Dear Editor,The coronavirus disease 2019(COVID-19)pandemic is generating a demand for simultaneous vaccine development,which is expected to prevent future outbreaks by eliciting sufficient and protective immunity.
Dear Editor,As the outbreak of coronavirus disease 2019(COVID-19)turns into a pandemic,it has literally caused a worldwide public health crisis.Progressive lymphopenia,especially in T cells,was a prominent clinical fe...Dear Editor,As the outbreak of coronavirus disease 2019(COVID-19)turns into a pandemic,it has literally caused a worldwide public health crisis.Progressive lymphopenia,especially in T cells,was a prominent clinical feature of severe COVID-19 in addition to dyspnea,hypoxemia,acute respiratory distress,and cytokine release syndrome.1 Recently,several studies revealed a correlation between T cell depletion and increased expression levels of several inhibitory checkpoint molecules on T cells in severe COVID-19 cases.2 Classically,inhibitory checkpoint molecules have been documented as key factors for regulating T cell exhaustion in a variety of chronic viral infections and tumors.Recent studies further implied a pivotal role of inhibitory checkpoint molecules in the pathophysiology of acute viral infections,such as Ebola virus or hantavirus infection.Of note,soluble isoforms of checkpoints can be produced by cleavage of membrane-bound proteins or by alternative splicing of mRNA and competitively regulate the functions of their membrane-bound counterparts.3 Thus it is of great interest to determine whether soluble checkpoint molecules are involved in immune regulation and severity of COVID-19.展开更多
基金supported by the Strategic Priority Research Program of the Chinese Academy of Sciences(CAS)(XDB29010102)the National Natural Science Foundation of China(NSFC)(32041010)+4 种基金Beijing Municipal Science&Technology Commission(Z201100007920017)Beijing Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support(ZYLX201802)Beijing Hospital Authority(DFL20191801)the NSFC Outstanding Young Scholars(31822055)the Youth Innovation Promotion Association of CAS(2017122)。
文摘Dear Editor,The coronavirus disease 2019(COVID-19)pandemic is generating a demand for simultaneous vaccine development,which is expected to prevent future outbreaks by eliciting sufficient and protective immunity.
基金supported by Capital Clinical Characteristic Application(Z171100001017052)National Key Sci-Tech Special Project of China(2018ZX10302207)+1 种基金Beijing Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support(ZYLX201802)Beijing Hospital Authority(DFL20191801).
文摘Dear Editor,As the outbreak of coronavirus disease 2019(COVID-19)turns into a pandemic,it has literally caused a worldwide public health crisis.Progressive lymphopenia,especially in T cells,was a prominent clinical feature of severe COVID-19 in addition to dyspnea,hypoxemia,acute respiratory distress,and cytokine release syndrome.1 Recently,several studies revealed a correlation between T cell depletion and increased expression levels of several inhibitory checkpoint molecules on T cells in severe COVID-19 cases.2 Classically,inhibitory checkpoint molecules have been documented as key factors for regulating T cell exhaustion in a variety of chronic viral infections and tumors.Recent studies further implied a pivotal role of inhibitory checkpoint molecules in the pathophysiology of acute viral infections,such as Ebola virus or hantavirus infection.Of note,soluble isoforms of checkpoints can be produced by cleavage of membrane-bound proteins or by alternative splicing of mRNA and competitively regulate the functions of their membrane-bound counterparts.3 Thus it is of great interest to determine whether soluble checkpoint molecules are involved in immune regulation and severity of COVID-19.
